About this trial
Pubertal transition leads to enduring neuroendocrine changes along with changes in the epigenome. The prevalence of psychiatric disorders significantly increases in females compared to males after puberty. There is likely to be an interaction between epigenetics, hormones and neurophysiological processes during puberty, leading to the increased prevalence of mental disorders in females. This study aims to shed light on these interactions underlying the emerging sex differences after puberty. Specifically, it seeks to investigate the epigenetic modifications and subsequent changes in gene expression during the pubertal transition and their association with negative emotionality (e.g., acute stress response and depressive symptoms) at molecular, neuronal, subjective and physiological levels.
Eligibility criteria
Qualifiers
healthy girls
aged between 8-10 and having pubertal stage 1 or between 15-17 and having pubertal stage 5
normal body mass index according to age (between 5th and 85th percentile)
non-smoking
Disqualifiers
neurological or psychiatric disease
medical problems such as hormonal, metabolic, developmental or chronic diseases (e.g., congenital disorders, precocious puberty, polycystic ovarian syndrome, diabetes or congestive heart failure)
any kind of hormonal, pharmacological or psychotropic treatment in the last three months
engaging in competitive/extreme sports
Trial design
Treatments tested in this trial
- Stress
Treatment groups
Sponsors and collaborators
International Research Training Group 2804
Lead sponsor
University Hospital Tuebingen
Collaborator
Uppsala University
Collaborator
German Research Foundation
Collaborator